R&D News | pharmaphorum

News

Chiesi Biotech Center of Excellence opens to strengthen R&D ...

Chiesi Group has today officially launched its new Biotech Center of Excellence, with the aim that it "brings the future of medicine to Parma."

News

SEC charges Cassava over 'misleading' Alzheimer's claims

The US financial regulator has accepted a $40 million-plus settlement from Cassava Sciences and two of its former executives for making what it alleges are misleading statements about the r

News

Vicebio raises $100m for vaccines and other bio financings

Our periodic round-up of financings in the biotech sector is led by an impressive nine-figure round for UK vaccines developer Vicebio, with GC Therapeutics, Genespire, and 858 Therapeutics

News

Mirai Bio launches with plan to help genetic med developers

Flagship Pioneering's latest biotech launch, Mirai Bio, aims to help genetic medicine developers find the best way to get their drugs to patients.

News

Kristen Fortney, CEO and co-founder of BioAge Labs

Obesity drug developer BioAge raises $198m in IPO

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%.

News

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

Chiesi Biotech Center of Excellence opens to strengthen R&D ...

SEC charges Cassava over 'misleading' Alzheimer's claims

Vicebio raises $100m for vaccines and other bio financings

Mirai Bio launches with plan to help genetic med developers

Obesity drug developer BioAge raises $198m in IPO

MSD hits a hurdle with its LAG-3 programme

UK's Claret Capital raises €575m for European biotechs

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks